ReviewJournal of clinical and experimental hepatology
2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.Hepatology international · 2024Guideline
- Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.Radiation oncology (London, England) · 2026Article
- NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin.iScience · 2026Article
- Stereotactic body radiation therapy in patients with unresectable hepatocellular carcinoma and portal vein tumor thrombosis.World journal of hepatology · 2025Article
- Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study.International journal of clinical oncology · 2025Article
- Article
- Review
- Surgical treatment for hepatocellular carcinoma in era of multidisciplinary strategies.International journal of clinical oncology · 2025Review
- Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.Journal of clinical and experimental hepatologyReview
- Living Donor Liver Transplantation for Hepatocellular Carcinoma.Journal of clinical and experimental hepatologyReview
- Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.Journal of clinical and experimental hepatologyReview
- Liver Resection for Hepatocellular Carcinoma: Recent Advances.Journal of clinical and experimental hepatologyReview
- Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision.Journal of clinical and experimental hepatologyReview
- Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024.Journal of clinical and experimental hepatologyReview
- Predictive Factors and Nomogram (MAP-BNP) for Post Stereotactic Body Radiotherapy Survival in Advanced Hepatocellular Carcinoma Patients.Journal of clinical and experimental hepatologyArticle
- Recent Advances in Ablative Therapies for HCC.Journal of clinical and experimental hepatologyReview
- Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma in 2025.Journal of clinical and experimental hepatologyReview
- Hepatocellular Carcinoma: Molecular Diagnosis and Perspectives for Therapy.Journal of clinical and experimental hepatologyArticle
- Co-relation of Portal Vein Tumour Thrombus Response With Survival Function Following Robotic Radiosurgery in Vascular Invasive Hepatocellular Carcinoma.Journal of clinical and experimental hepatologyArticle
- IMbrave050 Study: A Revolutionary Breakthrough in Hepatocellular Carcinoma Adjuvant Therapy.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) presents significant treatment challenges despite considerable advancements in its management. The Indian National Association for the Study of the Liver (INASL) first published its guidelines to aid healthcare professionals in the diagnosis and treatment of HCC in 2014. These guidelines were subsequently updated in 2019. However, INASL has recognized the need to revise its guidelines in 2023 due to recent rapid advancements in the diagnosis and management of HCC, particularly for intermediate and advanced stages. The aim is to provide healthcare professionals with evidence-based recommendations tailored to the Indian context. To accomplish this, a task force was formed, and a two-day round table discussion was held in Puri, Odisha. During this event, experts in their respective fields deliberated and finalized consensus statements to develop these updated guidelines. The 2023 INASL guidelines offer a comprehensive framework for the diagnosis, staging, and management of intermediate and advanced HCC in India. They represent a significant step forward in standardizing clinical practices nationwide, with the primary objective of ensuring that patients with HCC receive the best possible care based on the latest evidence. The guidelines cover various topics related to intermediate and advanced HCC, including biomarkers of aggressive behavior, staging, treatment options, and follow-up care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.